Press Releases

  MAY 10, 2013
NEW STORY CEL-SCI Corporation Reports Second Quarter 2013 Financial Results
  MAY 6, 2013
NEW STORY CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model
  MAY 3, 2013
NEW STORY CEL-SCI to Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4th
  APRIL 23, 2013
NEW STORY CEL-SCI Corporation Provides Update on Phase III Clinical Trial
  APRIL 8, 2013
NEW STORY CEL-SCI Corporation Announces That NIAID Collaborators Have Submitted Bird Flu Study for Publication to Prestigious Scientific Journal
  FEBRUARY 25, 2013
NEW STORY CEL-SCI Announces Initiation of New Sites for Multikine Phase III Clinical Study for Head and Neck Cancer in Taiwan
  FEBRUARY 8, 2013
CEL-SCI Corporation Reports First Quarter 2013 Financial Results
  FEBRUARY 7, 2013
CEL-SCI to Present at 15TH Annual BIO CEO & Investor Conference
  JANUARY 31, 2013
CEL-SCI and Northeast Ohio Medical University Develop Novel Cancer Vaccine That Prevents and Treats Breast Cancer
  DECEMBER 14, 2012
CEL-SCI Corporation Announces Fiscal 2012 Financial Results
  DECEMBER 4, 2012
CEL- SCI Corporation to Raise $10.5 Million in Registered Direct Offering
  NOVEMBER 30, 2012
CEL-SCI Corporation Releases Letter to Shareholders
  NOVEMBER 28, 2012
CEL-SCI Receives Key Japanese Patent for Its Investigational Phase III Cancer Therapy Multikine
  OCTOBER 22, 2012
CEL-SCI Corporation Announces Results Of Interim Review Of Data From Its Ongoing Phase III Head And Neck Cancer Trial By Independent Data Monitoring Committee (IDMC)
  AUGUST 9, 2012
CEL-SCI Corporation Reports Third Quarter 2012 Financial Results
  JUNE 19, 2012
CEL- SCI Corporation to Raise $5.60 Million in Registered Direct Offering
  MaY 18, 2012
CEL- SCI Corporation Releases Letter to Shareholders
  MaY 15, 2012
CEL-SCI'S Chief Scientific Officer Presents at Cancer Symposium
  MaY 10, 2012
CEL-SCI Corporation Reports Second Quarter 2012 Financial Results
  March 6, 2012
CEL-SCI Corporation Pays Off Convertible Debenture
  February 9, 2012
CEL-SCI Corporation Reports First Quarter 2012 Financial Results
  January 26, 2012
CEL- SCI Corporation to Raise $5.76 Million in Registered Direct Offering
  January 20, 2012
CEL- SCI Corporation Releases Letter to Shareholders
  December 27, 2011
CEL- SCI Corporation Authorizes Expansion of Phase III Clinical Trial to an Additional 4 European Countries
  December 23, 2011
CEL-SCI Corporation Announces Fiscal 2011 Financial Results
  December 7, 2011
CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)
  November 2, 2011
CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)
  October 7, 2011
CEL-SCI Corporation Announces the Closing of Its $4 Million Registered Direct Offering of Common Stock and Warrants
  October 4, 2011
CEL-SCI Corporation to Raise $4 Million In Registered Direct Offering
  AUGUST 23, 2011
CEL-SCI Announces Exclusive Sales, Marketing and Distribution Agreement for Its Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection) for Argentina and Venezuela
  AUGUST 18, 2011
CEL-SCI Addresses Warning Letter in Regard to Statements on Its Corporate Website
  AUGUST 17, 2011
CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)

 

 

News & Announcements

 

  

Sign Up For News